• September 28, 2022


In late June 2022, Sanas, a Silicon Valley startup, raised $32 million in Series A funding. Sanas is a real-time accent translation technology. For years, call centers in India or the …

New Microsoft Documents Reveal Surprising Surface Plans

Next month’s Microsoft event is widely expected to launch a number of new Surface devices, including an update to the flagship range with the Surface Pro 9 and the next version …

Review: Hands On With Creative’s Battery Champ, Outlier Pro Wireless Earbuds

Creative Technology is a company that’s well known for computer audio (Sound Blaster sound cards) and speakers. I’ve had some excellent experiences with Creative Katana gaming soundbars and iRoar Bluetooth speakers …

Fosun Pharmaceutical, the pharmaceutical arm of investment firm Fosun International controlled by China billionaire Guo Guangchang, will pay up to S$217.6 million, or $158 million, for a 60% stake in one of Singapore’s largest operators of cancer treatment centers.

The business, OncoCare Medical, has seven clinics in major private medical centers in Singapore, including the only private medical oncology medical center for women in the city-state, Fosun Pharma said. OncoCare is “well regarded for treatment of breast cancer, lung cancer, and colorectal cancer,” it added.

The investment will contribute to the expansion of Fosun Pharma’s medical services business in Southeast Asia and further strengthen its cancer treatment services overall, Fosun Pharma said.

Most of the shares – a 51% stake in OncoCare – are being sold by Aurora Healthcare, a company controlled by China pharmaceutical industry entrepreneur Liu Dianbo, the chairman of Hong Kong-listed Luye Pharmaceutical.

Guo is worth $4.6 billion on the Forbes Real-Time Billionaires List today.


Fosun Pharmaceutical’s shares have lost nearly 30% in the last year.

See related posts:

The 10 Richest Chinese Billionaires 2022

China Stocks And Shanghai Dwellers Enjoy A Big Day As Lockdowns Ease



Leave a Reply

Your email address will not be published.